Beruflich Dokumente
Kultur Dokumente
Key facts
Antimicrobial resistance (AMR) threatens the effective prevention and
treatment of an ever-increasing range of infections caused by bacteria,
parasites, viruses and fungi.
AMR is an increasingly serious threat to global public health that requires
action across all government sectors and society.
Without effective antibiotics, the success of major surgery and cancer
chemotherapy would be compromised.
The cost of health care for patients with resistant infections is higher than
care for patients with non-resistant infections due to longer duration of
illness, additional tests and use of more expensive drugs.
Globally, 480 000 people develop multi-drug resistant TB each year, and
drug resistance is starting to complicate the fight against HIV and malaria,
as well.
What is antimicrobial resistance?
animals, and from person to person. Poor infection control, inadequate sanitary
conditions and inappropriate food-handling encourage the spread of antimicrobial
resistance.
Present situation
Resistance in bacteria
Antibiotic resistance is present in every country.
Patients with infections caused by drug-resistant bacteria are at increased risk of
worse clinical outcomes and death, and consume more health-care resources
than patients infected with non-resistant strains of the same bacteria.
Resistance in Klebsiella pneumoniae common intestinal bacteria that can cause
life-threatening infections to a last resort treatment (carbapenem antibiotics)
has spread to all regions of the world. K. pneumoniae is a major cause of
hospital-acquired infections such as pneumonia, bloodstream infections, and
infections in newborns and intensive-care unit patients. In some countries,
because of resistance, carbapenem antibiotics do not work in more than half of
people treated for K. pneumoniae infections.
Resistance in E. coli to one of the most widely used medicines for the treatment
of urinary tract infections (fluoroquinolone antibiotics) is very widespread. There
are countries in many parts of the world where this treatment is now ineffective
in more than half of patients.
Treatment failure to the last resort of medicine for gonorrhoea (third generation
cephalosporin antibiotics) has been confirmed in at least 10 countries (Australia,
Austria, Canada, France, Japan, Norway, Slovenia, South Africa, Sweden and the
United Kingdom of Great Britain and Northern Ireland).
WHO recently updated the treatment guidelines for gonorrhoea to address
emerging resistance. The new WHO guidelines do not recommend quinolones (a
class of antibiotic) for the treatment of gonorrhoea due to widespread high levels
of resistance. In addition, treatment guidelines for chlamydial infections and
syphilis were also updated.
Resistance to first-line drugs to treat infections caused by Staphlylococcus
aureusa common cause of severe infections in health facilities and the
communityis widespread. People with MRSA (methicillinresistant Staphylococcus aureus) are estimated to be 64% more likely to die than
people with a non-resistant form of the infection.
Colistin is the last resort treatment for life-threatening infections caused by
Enterobacteriaceae which are resistant to carbapenems. Resistance to colistin
has recently been detected in several countries and regions, making infections
caused by such bacteria untreatable.
Resistance in tuberculosis (TB)
WHO estimates that, in 2014, there were about 480 000 new cases of multidrugresistant tuberculosis (MDR-TB), a form of tuberculosis that is resistant to the 2
most powerful anti-TB drugs. Only about a quarter of these (123 000 cases) were
detected and reported. MDR-TB requires treatment courses that are much longer
and less effective than those for non-resistant TB. Globally, only half of MDR-TB
patients were successfully treated in 2014.